New eye injection shows promise for diabetic vision loss
NCT ID NCT05959304
First seen Jan 04, 2026 · Last updated May 18, 2026 · Updated 28 times
Summary
This study tested a drug called brolucizumab, given as eye injections, in 66 adults with diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The goal was to check safety and how well it works in a real-world setting in India. Participants received injections over 40 weeks, and researchers tracked side effects and vision changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380052, India
-
Novartis Investigative Site
Bangalore, Karnataka, 560 010, India
-
Novartis Investigative Site
Kochi, Kerala, 682 026, India
-
Novartis Investigative Site
Chennai, Tamil Nadu, 600045, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700 073, India
-
Novartis Investigative Site
Coimbatore, 641002, India
-
Novartis Investigative Site
Kolkata, 700120, India
-
Novartis Investigative Site
New Delhi, 110029, India
Conditions
Explore the condition pages connected to this study.